Emergent Biosolutions
EBS
224 hedge funds and large institutions have $1.02B invested in Emergent Biosolutions in 2016 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 101 increasing their positions, 60 reducing their positions, and 27 closing their positions.
68% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 60
48% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 27
6.51% more ownership
Funds ownership: 85.1% → 91.61% (+6.5%)
5% more funds holding
Funds holding: 214 → 224 (+10)
16% less capital invested
Capital invested by funds: $1.22B → $1.02B (-$197M)
84% less call options, than puts
Call options by funds: $1.67M | Put options by funds: $10.6M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$22.4M |
| 2 |
Goldman Sachs
New York
|
+$22.2M |
| 3 |
MFIMFI
Mesirow Financial Investment Management - Fixed Income
Chicago,
Illinois
|
+$21.5M |
| 4 |
Morgan Stanley
New York
|
+$19.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$31.8M |
| 2 |
Bank of New York Mellon
New York
|
-$26.8M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$15.6M |
| 4 |
ICRM
Insight Capital Research & Management
Walnut Creek,
California
|
-$7.39M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$7.11M |
EBS Hedge Fund Activity: Q2 2016 in Review
224 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q2 2016, worth a combined $1.02B — down 16% from $1.22B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new EBS positions and 27 closed out — a net gain of 13 holders — while 101 added to existing stakes and 60 trimmed.
The largest buyer was Fidelity International, opening a new position worth an estimated $22.4M. The largest seller was Loomis, Sayles & Company, cutting an estimated $31.8M.
- 224 institutional investors held Emergent Biosolutions (EBS) as of Q2 2016, up from 214 in Q1 2016.
- Funds reported $1.02B of Emergent Biosolutions stock for Q2 2016, down 16% quarter-over-quarter.
- 40 funds opened new Emergent Biosolutions positions in Q2 2016 and 27 closed out, a net change of +13 holders.
- The largest Emergent Biosolutions buyer in Q2 2016 was Fidelity International, an estimated $22.4M added.
- The largest Emergent Biosolutions seller in Q2 2016 was Loomis, Sayles & Company, an estimated $31.8M sold.
Based on aggregated 13F filings for Q2 2016.